» Articles » PMID: 36220689

MiRNA Effects on Gut Homeostasis: Therapeutic Implications for Inflammatory Bowel Disease

Overview
Journal Trends Immunol
Date 2022 Oct 11
PMID 36220689
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel disease (IBD) spans a range of chronic conditions affecting the gastrointestinal (GI) tract, which are marked by intermittent flare-ups and remissions. IBD results from microbial dysbiosis or a defective mucosal barrier in the gut that triggers an inappropriate immune response in a genetically susceptible person, altering the immune-microbiome axis. In this review, we discuss the regulatory roles of miRNAs, small noncoding RNAs with gene regulatory functions, in the stability and maintenance of the gut immune-microbiome axis, and detail the challenges and recent advances in the use of miRNAs as putative therapeutic agents for treating IBD.

Citing Articles

Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date.

Giammona A, Galuzzi B, Imperia E, Gervasoni C, Remedia S, Restaneo L Int J Mol Sci. 2025; 26(1.

PMID: 39796266 PMC: 11720538. DOI: 10.3390/ijms26010413.


Importance of Fecal Microbiota Transplantation and Molecular Regulation as Therapeutic Strategies in Inflammatory Bowel Diseases.

Brusnic O, Olga B, Boicean A, Adrian B, Fleaca S, Sorin-Radu F Nutrients. 2025; 16(24).

PMID: 39771031 PMC: 11676862. DOI: 10.3390/nu16244411.


Probiotics Exert Gut Immunomodulatory Effects by Regulating the Expression of Host miRNAs.

Li W, Zeng Y, Zhong J, Hu Y, Xiong X, Zhou Y Probiotics Antimicrob Proteins. 2025; .

PMID: 39754704 DOI: 10.1007/s12602-024-10443-9.


MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease.

Ramadan Y, Kamel A, Medhat M, Hetta H Clin Exp Med. 2024; 24(1):217.

PMID: 39259390 PMC: 11390904. DOI: 10.1007/s10238-024-01476-z.


Apolipoprotein A-I: Potential Protection Against Intestinal Injury Induced by Dietary Lipid.

Wang J, Yu S, Huang G, Yu Y, Li Y J Inflamm Res. 2024; 17:5711-5721.

PMID: 39219814 PMC: 11366247. DOI: 10.2147/JIR.S468842.


References
1.
Chen P, Huang S, Yu Q, Chao K, Wang Y, Zhou G . Serum exosomal microRNA-144-3p: a promising biomarker for monitoring Crohn's disease. Gastroenterol Rep (Oxf). 2022; 10:goab056. PMC: 8973006. DOI: 10.1093/gastro/goab056. View

2.
Baumjohann D, Kageyama R, Clingan J, Morar M, Patel S, de Kouchkovsky D . The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013; 14(8):840-8. PMC: 3720769. DOI: 10.1038/ni.2642. View

3.
Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S . Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell Mol Immunol. 2014; 11(5):495-502. PMC: 4197204. DOI: 10.1038/cmi.2014.30. View

4.
Ge J, Huang Z, Liu H, Chen J, Xie Z, Chen Z . Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. Front Immunol. 2017; 8:1173. PMC: 5614978. DOI: 10.3389/fimmu.2017.01173. View

5.
Vigorito E, Perks K, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S . microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007; 27(6):847-59. PMC: 4135426. DOI: 10.1016/j.immuni.2007.10.009. View